Participants
We included symptomatic and asymptomatic children in both inpatient and ambulatory settings seeking care at CHCO who were immunocompromised and had at least 1 positive SARS-CoV-2 PCR conducted at the CHCO Clinical Microbiology Laboratory. Children were defined as immunocompromised if they were a patient of the CCBD receiving active treatment for cancer (solid and liquid tumor), post bone marrow/stem cell transplant or chimeric antigen receptor- (CAR) T cell therapy with active documented immunodeficiency, had a primary or secondary immunodeficiency (e.g. HIV) or received immunosuppressive medications. We excluded children with normal immune function and those not currently on treatment for their cancer diagnosis, fully immune reconstituted post-bone marrow transplant, and those with a positive SARS-CoV-2 test at outside facilities only. Our institution requires ICC to have two consecutive negative SARS-CoV-2 PCR tests collected at least 24 hours apart and 21 days from the patient’s initial positive test in order to be removed from isolation.